Trevi Therapeutics, Inc. (TRVI)
Largest Insider Buys in Sector
TRVI Stock Price History Chart
TRVI Stock Performance
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in …
Insider Activity of Trevi Therapeutics, Inc.
Over the last 12 months, insiders at Trevi Therapeutics, Inc. have bought $0 and sold $570,473 worth of Trevi Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Trevi Therapeutics, Inc. have bought $22.8M and sold $251,021 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,631,578 shares for transaction amount of $5M was made by NEA 16 GP, LLC () on 2022‑04‑11.
List of Insider Buy and Sell Transactions, Trevi Therapeutics, Inc.
| 2024-09-09 | Sale | President & CEO | 1,840 0.0025% | $3.04 | $5,587 | +0.96% | ||
| 2024-09-06 | Sale | President & CEO | 4,219 0.006% | $3.03 | $12,784 | +6.78% | ||
| 2024-09-05 | Sale | President & CEO | 40,277 0.0557% | $3.11 | $125,310 | +1.61% | ||
| 2024-09-04 | Sale | President & CEO | 10,981 0.0155% | $3.02 | $33,205 | +6.27% | ||
| 2024-09-03 | Sale | President & CEO | 3,863 0.0054% | $3.02 | $11,677 | +5.05% | ||
| 2024-08-27 | Sale | director | 4,555 0.0063% | $2.93 | $13,353 | +7.22% | ||
| 2024-08-19 | Sale | Chief Scientific Officer | 16,496 0.0227% | $2.96 | $48,883 | +4.71% | ||
| 2024-08-16 | Sale | Chief Scientific Officer | 18,660 0.0268% | $2.76 | $51,440 | +7.74% | ||
| 2024-08-15 | Sale | Chief Scientific Officer | 12,745 0.0185% | $2.79 | $35,513 | 0.00% | ||
| 2024-08-14 | Sale | Chief Scientific Officer | 100 0.0001% | $2.75 | $275 | 0.00% | ||
| 2024-05-29 | Sale | Chief Scientific Officer | 53,368 0.0761% | $2.55 | $136,110 | +16.60% | ||
| 2024-05-22 | Sale | Chief Financial Officer | 4,350 0.0062% | $2.64 | $11,485 | +12.17% | ||
| 2024-05-20 | Sale | President & CEO | 25,037 0.0359% | $2.86 | $71,576 | +4.24% | ||
| 2024-05-10 | Sale | President & CEO | 4,578 0.0069% | $2.90 | $13,276 | +6.59% | ||
| 2023-10-11 | Sale | Chief Financial Officer | 785 0.0012% | $2.02 | $1,586 | +29.90% | ||
| 2023-09-11 | Sale | Chief Financial Officer | 711 0.0011% | $2.20 | $1,564 | +12.39% | ||
| 2023-08-11 | Sale | Chief Financial Officer | 682 0.0011% | $2.36 | $1,610 | -5.04% | ||
| 2023-07-11 | Sale | Chief Financial Officer | 687 0.0007% | $2.34 | $1,608 | -1.32% | ||
| 2023-06-12 | Sale | Chief Financial Officer | 610 0.0006% | $2.64 | $1,610 | -11.72% | ||
| 2023-05-11 | Sale | Chief Financial Officer | 562 0.0008% | $2.89 | $1,624 | -25.50% |
Insider Historical Profitability
| Meeker David P | director | 352489 0.4856% | $3.06 | 1 | 1 | <0.0001% |
| GOOD JENNIFER L | President & CEO | 213313 0.2939% | $3.06 | 1 | 7 | <0.0001% |
| BASKETT FOREST | 10421428 14.3562% | $3.06 | 3 | 1 | +1.73% | |
| Makhzoumi Mohamad | 10421428 14.3562% | $3.06 | 3 | 1 | +1.73% | |
| NEA 16 GP, LLC | 10421428 14.3562% | $3.06 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Nea Management Company Llc | $39.23M | 16.14 | 11.37M | 0% | +$0 | 0.18 | |
| Frazier Life Sciences Management L P | $25.46M | 10.48 | 7.38M | 0% | +$0 | 1.15 | |
| Helm Capital Management LLC | $19.2M | 7.9 | 5.56M | -2.12% | -$415,024.64 | 0.57 | |
| Viking Global Investors | $15.18M | 6.25 | 4.4M | 0% | +$0 | 0.01 | |
| Vr Adviser Llc | $11.81M | 4.86 | 3.42M | +<0.01% | +$959.10 | 0.57 |